48
Participants
Start Date
August 31, 2016
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
TetraVax-DV-TV005
TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
rDEN3Δ30
Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
Placebo
Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore
University of Vermont Testing Center, Burlington
National Institute of Allergy and Infectious Diseases (NIAID)
NIH